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Clinical, biochemical and molecular biology studies have identified lysosome-encapsulated 
cellular proteases as critical risk factors for cancer progression. Cathepsins represent a group of 
such proteases aimed at maintenance of cellular homeostasis. Nevertheless, recent reports 
suggest that Cathepsin B executes other cellular programs such as controlling tumor growth, 
migration, invasion, angiogenesis, and metastases development. In fact, elevated levels of 
Cathepsins are found under different pathological conditions including inflammation, infection, 
neurodegenerative disease, and cancer. Furthermore, the discovery of Cathepsin B secretion and 
function as an extracellular matrix protein has broadened our appreciation for the impact of 
Cathepsin B on cancer progression. Underneath a façade of an intracellular protease with limited 
therapeutic potential hides a central role of cathepsins in extracellular functions. Moreover, this 
role is incredibly diverse from one condition to the next – from driving caspase-dependent 
apoptosis to facilitating tumor neovascularization and metastasis. Here we discuss the role of 
Cathepsin B in the oncogenic process and perspective the use of Cathepsin B for diagnostic and 
therapeutic applications. 
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Table 2. Cathepsin B inhibitors and their appropriate mechanism of action available to inhibit cathepsin B 
Inhibitor Chemistry Mechanism Source Reference 
Z-Phe-AlaCH2F 
fluoromethyl ketone 
3-(N-
benzyloxycarbonylphenylalanylamido)-
DL-1-fluoro-2-butanone 
Irreversible 
covalent 
inhibitor 
synthesized 
Rasnick D. Synthesis of peptide fluoromethyl 
ketones and the inhibition of human Cathepsin B. 
Anal Biochem. 1985 Sep;149(2):461-5. 
E-64 C15N5H2705 
Irreversible 
covalent 
inhibitor 
Aspergillus 
japonicus 
TPR-64 
Hanada K, Tamai M, Yamagishi M, Ohmura S, 
Sawada J, Tanaka I. Isolation and characterization 
of E-64, a new thiol protease inhibitor. Agric Biol 
Chem. 1978;42:523–528. 
E64d 
EST, Loxistatin, ethyl (2S,3S)-3-
[[(2S)-4-methyl-1-(3-
methylbutylamino)-1-oxopentan-2-
yl]carbamoyl]oxirane-2-carboxylate 
Irreversible 
covalent 
inhibitor 
synthesized 
Hashida S, Towatari T, Kominami E, Katunuma N. 
Inhibitions by E-64 derivatives of rat liver 
Cathepsin B and Cathepsin L in vitro and in vivo. J 
Biochem. 1980 Dec;88(6):1805-11. 
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iodo and 
diiodotyrosine E-
64-c analogs 
Iodo and diiodotyrosine epoxysuccinyl 
derivatives 
Irreversible 
covalent 
inhibitor 
synthesized 
Giordano C, Calabretta R, Gallina C, Consalvi V, 
Scandurra R, Noya FC. Iodo and diiodotyrosine 
epoxysuccinyl derivatives as selective inhibitors of 
Cathepsin B. Eur J Med Chem. 1993;28:917–926. 
CA-074 and its 
derivates ( CA-
074 Me) 
[L-3-trans-(propylcarbamoyl)oxirane-
2- carbonyl]-L-isoleucyl-L-proline 
Irreversible 
covalent 
inhibitor 
synthesized 
Montaser M, Lalmanach G, Mach L. CA-074, but 
not its methyl ester CA-074Me, is a selective 
inhibitor of Cathepsin B within living cells. Biol 
Chem. 2002 Jul-Aug;383(7-8):1305-8. 
Miraziridine A aziridinylpeptide 
Irreversible 
covalent 
inhibitor 
Theonella 
mirabilis 
Theonella 
swinhoei 
Nakao Y, Fujita M, Warabi K, Matsunaga S, 
Fusetani N. Miraziridine A a novel cysteine 
protease inhibitor from the marine sponge theonella 
aff. mirabilis. J Am Chem Soc. 2000;122:10462–
10463. 
Bz-Phe-Arg- peptide derivative of 
Irreversible 
covalent 
synthesized 
Angliker H, Wikström P, Rauber P, Stone S, Shaw 
E. Synthesis and properties of peptidyl derivatives 
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CH2F arginylfluoromethane inhibitor of arginylfluoromethanes. Biochem J. 1988 Dec 
1;256(2):481-6. 
diazomethyl 
ketones 
Benzyloxycarbonyl-phenylalanyl 
diazomethyl ketone and benzyloxy-
carbonyl-phenylalanyl-phenylalanyl 
diazomethyl ketone 
Irreversible 
covalent 
inhibitor 
synthesized 
Leary R, Shaw E. Inactivation of Cathepsin B1 by 
diazomethyl ketones. Biochem Biophys Res 
Commun. 1977 Dec 7;79(3):926-31. 
peptidyl 
(acyloxy)methanes 
peptidyl (acyloxy)methanes 
Irreversible 
covalent 
inhibitor 
synthesized 
Krantz A. Peptidyl (acyloxy)methanes as quiescent 
affinity labels for cysteine proteinases. Methods 
Enzymol. 1994;244:656-71. 
1,2,4-thiadiazole 
derivate 
thiadiazoles 3a–h 
Irreversible 
covalent 
inhibitor 
synthesized 
Leung-Toung R, Wodzinska J, Li W, Lowrie J, 
Kukreja R, Desilets D, Karimian K, Tam TF. 1,2,4-
thiadiazole: a novel Cathepsin B inhibitor. Bioorg 
Med Chem. 2003 Dec 1;11(24):5529-37. 
Calpain inhibitor N-Acetyl-Leu-Leu-Methional Reversible synthesized Sasaki T, Kishi M, Saito M, Tanaka T, Higuchi N, 
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II inhibitor Kominami E, Katunuma N, Murachi T. Inhibitory 
effect of di- and tripeptidyl aldehydes on calpains 
and Cathepsins. J Enzyme Inhib. 1990;3(3):195-
201. 
Peptidyl 
cyclopropenone 9 
Peptidyl cyclopropenone 9 (the S 
isomer) 
Reversible 
inhibitor 
synthesized 
Cohen M, Bretler U, Albeck A. Peptidyl 
cyclopropenones: reversible inhibitors, irreversible 
inhibitors, or substrates of cysteine proteases? 
Protein Sci. 2013 Jun;22(6):788-99. 
shRNA-CTSB#2 oligonucleotide 
RNA 
interference 
inhibitor 
synthesized 
Bao W, Fan Q, Luo X, Cheng WW, Wang YD, Li 
ZN, Chen XL, Wu D. Silencing of Cathepsin B 
suppresses the proliferation and invasion of 
endometrial cancer. Oncol Rep. 2013 
Aug;30(2):723-30. 
DARPin 8h6 ankyrin repeat protein 
antibody-drug 
conjugate like 
synthesized 
Kramer L, Renko M, Završnik J, Turk D, Seeger 
MA, Vasiljeva O, Grütter MG, Turk V, Turk B. 
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inhibitor Non-invasive in vivo imaging of tumour-associated 
Cathepsin B by a highly selective inhibitory 
DARPin. Theranostics. 2017 Jul 8;7(11):2806-21. 
Concanamycin A designated folimycin 
Indirect 
inhibitor (by 
specific 
inhibiton of V-
ATPase) 
synthesized 
Uhlman A, Folkers K, Liston J, Pancholi H, Hinton 
A. Effects of Vacuolar H(+)-ATPase Inhibition on 
Activation of Cathepsin B and Cathepsin L 
Secreted from MDA-MB231 Breast Cancer Cells. 
Cancer Microenviron. 2017 Dec;10(1-3):49-56. 
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Abstract 
Clinical, biochemical and molecular biology studies have identified lysosome-encapsulated cellular proteases as critical risk factors for cancer 
progression. Cathepsins represent a group of such proteases aimed at maintenance of cellular homeostasis. Nevertheless, recent reports suggest 
that Cathepsin B executes other cellular programs such as controlling tumor growth, migration, invasion, angiogenesis, and metastases 
development. In fact, elevated levels of Cathepsins are found under different pathological conditions including inflammation, infection, 
neurodegenerative disease, and cancer. Furthermore, the discovery of Cathepsin B secretion and function as an extracellular matrix protein has 
broadened our appreciation for the impact of Cathepsin B on cancer progression. Underneath a façade of an intracellular protease with limited 
therapeutic potential hides a central role of cathepsins in extracellular functions. Moreover, this role is incredibly diverse from one condition to 
the next – from driving caspase-dependent apoptosis to facilitating tumor neovascularization and metastasis. Here we discuss the role of 
Cathepsin B in the oncogenic process and perspective the use of Cathepsin B for diagnostic and therapeutic applications. 
 
1. Introduction  
In the last decade, cancer has evolved as one of the leading causes of death worldwide. The ability of cancer cells to maintain an internal 
homeostasis correlates with tumor aggressiveness and represents an essential characteristic of a neoplasm. Multiple pieces of evidence highlight 
the importance of lysosomes in cellular homeostasis [1, 2] and in developing cellular reaction[3, 4]. The fundamental role of these membrane-
bound organelles is the disposal and recycling of degraded macromolecules, along with digestion of alien structures that enter the cell via 
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phagocytosis [5]. Nevertheless, several studies established that under conditions of cellular stress the lysosome is involved in cellular adaptation, 
nutrient sensing [6], drug resistance[7, 8], immune response[9] and cell death[10]. Lysosomes contain more than 60 hydrolytic enzymes which 
include proteases, lipases, hydrolases, nucleases, glycosidases, phospholipases, phosphatases, and sulfatases [11].  
Tumor homeostasis is a multidimensional process that is regulated by cellular proteins, including cathepsin family of proteases, protein-
protein interactions, alternative splicing[12] and expression of miRNAs. Among the proteases, Cathepsin B is of most interest due to its central 
role in pathological processes. Cathepsin B is a critical element of lysosome cascade. It is a cysteine protease that is involved in the regulation of 
metalloproteinases[13, 14], intracellular communications, autophagy induction, and immune resistance. Moreover, the role of Cathepsin B in cell 
survival and the mechanisms of its execution are vastly diverse from one condition to the next – from driving caspase-dependent apoptosis to 
facilitating tumor neovascularization and metastasis. Herein, we review recent studies which investigate the role of Cathepsin B in pathological 
processes with a focus on cancer.  
2. Understanding the functions of Cathepsin B through the studies of its structure 
Cathepsin B is a member of a cysteine protease family. It acts through 3 isoforms: main transcript, main transcript lacking exon 2 or main 
transcript lacking exon 2 and 3 (Table 1). In a common opinion, the cytosomal localization of Cathepsin B dictates its main functions such as the 
turnover of cellular proteins[15]. However, other functions may include regulation of angiogenesis[16, 17], invasion[16, 18], tumor 
proliferation[18] and immune resistance[19], neurogenesis[20] cellular differentiation[21, 22], tumor response to hypoxia [23, 24]. Furthermore, 
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different Cathepsin B isoforms have differing subcellular localizations which may determine their distinct functions and independent regulation 
mechanisms[12, 25, 26]. 
Musil et al. created a model of the three-dimensional structure of Cathepsin B and established that the proteasomal function of 
Cathepsins requires the presence of specific structural features of the enzyme. In this structure, more than a third of amino acid residues are 
identical to the construction of protein papain, except for the covalently closed circular region between Cys108 and Cys119 residues (“occluding 
loop”)[27]. Cathepsin B is first expressed as a 44kDa inactive precursor which then undergoes maturation to produce a 33 kDa lysosome enzyme 
later converted to a final active form composed of two (24 and 5 kDa) subunits. The earliest studies demonstrated cathepsins to be most active in 
acidic conditions, and also to be released in an active form at low pH of the pericellular environment [28, 29]. Other reports described the pH-
dependent autoactivation of the zymogen pro-Cathepsin B, also showing that such pH-dependency could be alleviated with the introduction of 
glycosaminoglycans, explaining the wider window of optimal pH for Cathepsin B activity in vivo [30, 31]. Furthermore, the catalytic activity of 
Cathepsin B is dependent on the conformation of the “occluding loop”[32]. 
 
3. Cathepsin B in neurological disease: mechanism of action 
It is thought that active Cathepsin B is a carboxypeptidase, cleaving dipeptides from the C-terminus of protein substrates [15]. Such 
activity of Cathepsin B may regulate the rate of cell proliferation [33]. In pathological states where neurogenesis is impaired, and the rate of cell 
proliferation is decreased, such as Alzheimer’s disease [34] and Huntington’s disease[35], Cathepsin B plays a protective role by degrading 
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excessive amounts of misfolded protein inside the cell [26, 36]. In humans, the levels of Cathepsin B correlate with hippocampal-dependent 
memory functions and can be increased by physical exercise, while a Cathepsin B knock-down mice do not benefit from physical activity in 
terms of hippocampal neurogenesis and spatial memory [20]. On the other hand, the decrease in the rate of neurogenesis in AD can be secondary 
to the accumulation of the criticalAD proteins, which can be induced by inhibition of Cathepsin B and the consequent the lysosomal dysfunction 
[37]. 
It is also established that cells can secrete proteolytic enzymes as a means of execution of endocrine and nervous functions [38]. 
Specifically, the product of Cathepsin B transcript was found in the extracellular matrix (Table 1), suggesting enzyme release from active 
(proliferating) or passive (dead) cells, especially the cells growing under acidic pericellular conditions [11]. Extracellular release of lysosome-
based enzyme Cathepsin B has been implicated in the breakdown of the connective tissue of the extracellular matrix (ECM) [39] and shedding 
integrins [18] and angiogenesis factors which reduce tumor progression[40]. On the other hand, experimental evidence has implicated Cathepsin 
B in apoptosis regulation. In fact, the mitochondria-based caspase 9 and caspase 3 activation after lysosomal destabilization and Cathepsin B 
release into the cytoplasm exemplify pro-apoptotic function of Cathepsin B  [41]. The release of Cytochrome C (Cyt C) from mitochondria and 
its accumulation in the cytoplasm increases the affinity of procaspase effector Apaf-1 to ATP, which recruits procaspase-9 and initiates caspase 
3 activation to induce apoptosis [42, 43]. Cathepsin B can also function to induce apoptosis independently of caspase activation [44]. Separating 
caspase-dependent and caspase-independent cell death made it difficult to rationalize the biological significance of Cathepsin B for therapy, 
especially taking into consideration the more recent publications. Specifically, Alhajala et al. reported that radioresistant pediatric glioma exhibit 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
 
 
6 
 
a high level of MMP12, MMP19 and Cathepsin B [45], conferring dependency of glioma stress response on cellular proteases. Moreover, data 
from our investigation[46] and study performed by Hsu et al. suggest that targeting artificial autophagy[47] with either autophagy inducer, 
autophagy inhibitor or their combination may argument the anti-glioma effect of oncolytic adenovirus and/or temozolomide. These therapeutic 
combinations represent an advantageous approach that aims to convert the aborted autophagy to apoptosis via mitochondria damage or cathepsin 
B release. 
 
4. Interaction of Cathepsin B with cellular proteins: link to carcinogenesis 
The expression of Cathepsin B is elevated in many, but not all, cancers. In a screen of 501 randomly collected thyroid cancer human 
specimens, high expression of Cathepsin B promoted patient survival (Log Rank p=5.76e-4) (www.proteinatlas.org). Furthermore, in 
glioblastoma patients, high expression of Cathepsin B negatively correlated with the stage of the tumor (TCGA and Rembrandt Dataset). 
Conversely, in 406 patients with urothelial cancer, high expression of Cathepsin B negatively impacted patient survival (Log Rank, p=9.2e-4). ` 
Khan et al. demonstrated a negative correlation of Cathepsin B expression and laminin (ECM protein) in gastric[48] and colorectal 
carcinoma[49], suggesting the involvement of Cathepsin B in the remodeling of ECM. Examinations of the regulation of Cathepsin B by matrix 
proteins found that collagen I, through its interaction with α1β1 and α2β1 integrins, stimulated secretion of proCathepsin B by human breast 
fibroblasts. It was suggested that the effect may be executed at the post-transcriptional level because no change in mRNA level was found. It was 
also suggested that interaction of the fibroblasts with collagen I could increase translation or stabilize proCathepsin B protein [50]. 
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Skeletal muscle differentiation was also shown to be linked to the levels of expression and excretion of Cathepsin B[51]. Small et al. 
demonstrated that when smooth muscle cells shift  into a nonproliferative (contractile) state after termination of vascular reconstruction, 
expression of complement C1s, Cathepsin B, and cellular repressor of E1A-activated genes increased, as well as expression of Wilms’ tumor 1-
associating protein [52]. The forementioned evidence suggests the role of Cathepsin B in cellular differentiation that may have implications in 
cancer progression. 
The signaling cascades upstream of Cathepsin B were also worked out by previous studies. Glogowska et al. demonstrated that CTRP8 
(C1q-tumor necrosis factor-related protein 8) and RLN2 (relaxin isoform) hormone induce the production and secretion of Cathepsin B in 
glioblastoma cells, resulting in laminin degradation [53] and glioblastoma dissemination. Notably, the same group demonstrated the role of 
EGFcyt (Epidermal Growth Factor cytoplasmic domain) as an inducer of lysosomal procathB expression [54]. Recent mechanistic studies 
revealed a few novel regulators of Cathepsin B that facilitate either the pro-oncogenic function of Cathepsin B or its pro-apoptotic function. One 
of the regulators is metastasis-associated protein (MTA1) which inhibits Cathepsin B expression and is negatively correlated with E-Cadherin, 
critical for bone metastases progression [55]. Two other reports reveal that TNF-alpha enables the Bid-dependent lysosomal permeabilization, 
followed by the release of Cathepsin B into the cytosol, which facilitates mitochondrial cytochrome c release and apoptosis[56].  
The role of Cathepsin B-induced signaling in the promotion of tumorigenicity was also extensively studied. In fact, Yanamandra et al. 
and later Gupta et al. discovered that upregulation of Cathepsin B promotes angiogenesis via induction of VEGF-C and MMP-9 [17, 57]. On the 
contrary, in glioma, downregulation of uPAR in combination with Cathepsin B inhibits CD151 and α3β1-integrin-mediated adhesion and 
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invasion [58]. Later, Malla et al. suggest that downregulation of uPAR and Cathepsin B in glioma facilitates apoptosis through increased 
translocation of calcineurin from mitochondria to cytosol, decreased phosphorylation of BAD and increased interaction of BAD with Bcl-2 [59]. 
It is not surprising that Cathepsin B and uPAR downregulation work synergistically as anticarcinogenic mechanisms. This combination reduces 
p-ERK and c-Myc, which increases levels of E2F1 and FOXO3a, upregulating p27 expression in glioma cells [60]. The discovery of the 
interaction between Cathepsin B, MAPK, BAD and ERK[61] helped clarify the downstream targets of Cathepsin B and opened a new venue to 
design pharmacological combinatorial approaches to target Cathepsin B.   
 The feedback loop between Cathepsin B, MMP9 (metalloproteinase 9) and VEGF (vascular endothelial growth factor) highlight the role 
of the CTSB gene in tumor angiogenesis. On the one hand, expression of proangiogenic VEGF-A promotes the production of cathepsins 
including type B[62] by glioma cells to digest basal membrane[63] and stimulate endothelial cells to release the matrix-degrading enzymes. This 
enables glioma cells to form capillary sprouts via MMP9-regulated migration and proliferation. On the other hand, in neuroendocrine mouse 
tumors, levels of Cathepsin B and MMP9 are negatively correlated [64]. An earlier study on human glioblastoma cells showed that simultaneous 
inhibition of Cathepsin B and MMP-9 via RNA interference reduced tumor invasion, growth, and angiogenesis [16]. Similar results were 
produced when MMP-9, uPAR and Cathepsin B were inhibited in prostate cancer cells [65]. Ponnala et al. showed that silencing MMP-9 in vivo 
in combination with either uPAR or Cathepsin B resulted in suppression of aerobic glycolysis in glioma cells and switch to oxidative 
phosphorylation (OXPHOS) through inhibition of Akt, ultimately leading to the production  of ROS and accumulation of cytochrome C in the 
cytosol [66]. Although, as evidence from recent publication suggests that OXPHOS is mostly intact in cancer cells [67], the formation of 
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OXPHOS complex may preclude metabolic transformation of the cells from oxidative to glycolytic metabolism[68]. It was shown that 
fibronectin degradation by Cathepsin B allows the tumor cells to invade into the blood and lymphatic vessels of bladder carcinoma [69]. A 
similar conclusion may be drawn from the suppression of angiogenesis in glioblastomas lacking Cathepsin B.  Inhibition of Cathepsin B via 
RNA interference reduces VEGF release from cancer cells which prevent the development of microvessels [17]. Mai et al. and then Kong et al. 
suggested that Cathepsin B degradation of tenascin-C surrounding neovessels could facilitate neovascular extension resulting in the progression 
of gliomas[70, 71]. These findings present downregulation of Cathepsin B as a useful approach to target tumor neovascularization.  
 
5. Role of Cathepsin B modulation in anti-cancer therapy  
Stress stimulated secretion of Cathepsin B from the lysosomes, and its consequent cytoplasmic localization suggest a chain of events 
which may lead to toxicity. Time-dependent production of reactive oxygen species compromises the lysosomal integrity and is required for 
Cathepsin B and L activation and release [72]. Taking into consideration that the ROS may initiate cytoprotective and cytotoxic autophagy, it is 
reasonable to expect the involvement of Cathepsin B in both types of reaction depending on the stimulus. The main question is how to promote 
the Cathepsin-dependent cytotoxic autophagy and prevent the cytoprotective autophagy in cancer cells. For instance, Zhang et al. were able to 
inhibit the growth of non-small cell lung cancer in vivo via treatment with CA-5f (autophagosome-lysosome fusion inhibitor). Such treatment 
leads to an increase in ROS production, apoptosis, but no changes in the levels of Cathepsin B and D [73].  Another set of studies implicate 
Cathepsin B in the mechanisms of execution of cytotoxic effects of multiple anti-cancer drugs.                    Cathepsin B completely or partially 
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prevents toxicity of drugs such as HDAC [74], ERBB1/2/4 inhibitor neratinib [75], nilotinib [76], acid ceramidasa [77], Thymoquinone [78], 
Tyrosine kinase inhibitors (TKI) such as sunitinib, and pazopanib[79]. Han et al. showed that SAHA promotes cytotoxic autophagy via 
activation of Cathepsin B. Interestingly, a block of breast cancer cells treated with SAHA in the presence of siRNA against Cathepsin B or 
Cystatin C reduces apoptosis and promotes cell viability, also suggesting an intrinsic role of Cathepsin B in the SAHA-induced cytotoxicity[80] 
and establishing a link between Cathepsin B expression and cell survival. Mechanistically, it can be explained that increasing of lysosome 
membrane permeability and release of Cathepsin B may trigger late stages of autophagy which can be critical for drug toxicity. Regardless, all 
those possibilities need to be further investigated.  
On the other hand, autophagy is an essential cytoprotective system that is rapidly activated in response to various stimuli. In fact, Hong et 
al. revealed an increase in autophagy-related proteins Cathepsin B along with (ATG) 3, ATG7 and Rab7 during hepatic ischemia and perfusion 
[81]. In the same study, the necroptosis inhibitor Nec-1 attenuated those changes suggesting that Cathepsin B may be implicated in necroptotic 
cell death. Furthermore, Obatoclax (Bcl-2 family inhibitor) toxicity in oesophageal cancer is mediated by blockage of autophagic flux, evidenced 
by the concomitant accumulation of LC3-II and p62, and downregulation of lysosomal Cathepsins B, D, and L[82]. In the same study, Cathepsin 
knockdown induced cytotoxicity, suggesting compromised lysosomal function as a mechanism mediating the effect of Obatoclax on the 
progression of oesophageal cancer [82]. It is also significant to assess whether cytoprotective autophagy requires expression of Tumor Necrosis 
Factor Receptor-Associated Protein-1 (TRAP1), a homolog of mitochondrial-specific HSP90 [83]. This study observed decreased viability of 
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NSCLC cells upon inhibition of autophagy, but the stimulation of autophagy above the endogenous levels had a protective effect only in TRAP-
1 depleted cells. 
Although functional test data suggests a prosurvival function for Cathepsin B, it remains unknown how and when cytoprotective 
autophagy become cytotoxic and what is the molecular mechanism of that transformation. For instance, inhibition of PERK was shown to 
decrease the autophagic degradation of eLF2α and promoted cell survival.  Cathepsin B inhibitor CA074 also prevented IF2alpha from 
degradation, suggesting that Cathepsin B-mediated cytotoxic autophagy is PERK-dependent [84]. It is also unclear how malignant cells escape 
the cytotoxic autophagy. A recent report by Ning et al. identified a decrease in the levels of Cathepsin B along with other autophagic proteins in 
PTEN-knockdown Trastuzumab-resistant breast cancer cells [85].  
Another possibility for Cathepsin B to regulate autophagy is an opportunity to collaborate with other Cathepsin molecules of a different 
type. We speculate that each type of cells death is progressing through the involvement of several Cathepsins which together act as 
cytoprotective or cytotoxic triggers inside cells. For example, Liu et al. noted that the release of Cathepsin B and apoptosis induction occurs in 
the presence of Cathepsin D [86]. Multiple reports demonstrate that release of Cathepsin B alone in combination with an increase in expression 
of Cathepsin D [87, 88] and Cathepsin L [89] sensitize cancer cells to chemotherapeutic drugs via caspase-dependent and caspase-independent 
cell death.  
 
6. Cathepsin B is a target for therapy and diagnostics 
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An increasing number of studies highlight the role of autophagy and autophagy-related proteins in a broad range of physiological and 
pathological processes. The investigations of the molecular mechanisms of Cathepsin B regulation have attracted a lot of attention since this 
protein plays a pivotal role in autophagy-related events. Nowadays, Cathepsin B has become a cornerstone of novel therapeutic strategies.  
Tumor progression is a sequence of choreographed actions of transcriptional regulators, heavily influenced by cellular stress. Apart from 
transcriptional regulators, the activity of Cathepsin B is also regulated by endogenous inhibitors. Currently, four different inhibitors have been 
identified in the cystatin superfamily – stefins, kininogens, thyropins, and serpins[90]. Their function is to oversee the processes of biosynthesis 
and trafficking of Cathepsin B to lysosomes, as well as (auto-)proteolytic cleavage of pro-peptides (Fig. 1). Despite the potential known effect of 
the inhibitors on Cathepsin B, several studies reported on the metastasis suppressor function of the Cathepsin B inhibitors [91] in breast cancer 
[92], colorectal cancer [93], pancreatic ductal adenocarcinoma [94], etc. Despite the clear anti-tumor effect, each inhibitor has different efficacy 
against Cathepsin B.  
In recent years, the efforts of pharmacological research have been focused on targeting Cathepsin B specifically. For instance, the 
chemically designed Cathepsin B inhibitor ankyrin repeat protein DARP demonstrated more significant benefits for anti-cancer therapy and 
diagnostics. As shown by Kramer et al., application of DARP in 8h6 blocked Cathepsin B activity ex vivo and was useful to monitor tumor-
associated protein inhibition using non-invasive in vivo imaging [95]. Another report demonstrated that inhibition of vacuolar H+-ATPases (V-
ATPases) with concanamycin A decreased Cathepsin B activity in cell lysates of metastatic breast cancer cells [96]. Liow  et al. and Chow et al.  
recently found that Cathepsin B inhibitor benzyloxycarbonyl-phenylalanine-alanine-chloromethyl ketone (z-FA-CMK) induces apoptosis at low 
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concentrations and necrosis at higher concentrations in leukemic T cells via oxidative stress [97]. Most recently, Tang et al. reported a new 
autophagy inhibitor cepharanthine (CEP) with an anti-cancer effect on non-small lung cancer cells mediated by dacomitinib (DAC) via blockage 
of autophagosome-lysosome fusion and inhibition of lysosomal Cathepsin B and D maturation [98]. The full list of Cathepsin B inhibitor is 
presented at Tab.1. 
An increased level of Cathepsin B is already present in the lysosome, but it is nevertheless rapidly induced under various stimuli and 
leads to the production of prostaglandins, with subsequent inflammation via ATG7-dependent mechanism. Thus, it is believed that targeting of 
Cathepsin B via RNA interference may show a greater impact on Cathepsin B activity than chemical inhibitors due to lack of specificity. In fact, 
RNA interference oligonucleotide shRNA-CTSB#2 showed the most efficient inhibition of Cathepsin B at both mRNA and protein levels and 
resulted in suppressing endometrial cancer growth and development in vivo [33].  
Another approach which experimentally provided benefits for targeting lysosome is the application of cationic liposomes. Cationic 
liposomes induce lysosome membrane permeabilization and inhibit late-stage autophagic flux that results in the cytoplasmic release of Cathepsin 
B, mitochondrial dysfunction and production of reactive oxygen species followed by cell necrosis [99]. 
7. Conclusions 
In the last few decades, we are witnessing an exceptional stride in deciphering the perplexing biology of cathepsins in the normal and 
pathological environment. Owing to new techniques in genomics and proteomics, our knowledge of new functions and new substrates for each 
member of this group of proteins grows progressively [100]. Development of bioinformatics allows us to explore possible interactions between 
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Cathepsin B and potential inhibitors in silico [101]. Non-invasive in vivo imaging of cathepsins has potential in becoming a novel standard in 
diagnostics [95]. Despite the hope of using a chemical inhibitor of Cathepsin B, the possible application of designed drugs in clinics may be 
limited. First, we believe that the specificity of chemical inhibitors to Cathepsin B is a severe constraint for therapeutic use. In fact, the high 
expression of Cathepsin B in normal cells, as well as the promiscuous expression of Cathepsin B in tumor cells raise questions related to safety 
and specificity. Secondly, due to the multifaceted regulation of Cathepsin B signaling, chemical inhibition may stimulate alternative routes to 
restore the Cathepsin B levels (Tab. 2). That possibility raises concerns about modifications in the resistant cancer cell populations, leading to 
the formation of cells with unknown feedback loops or activation of other cathepsins. Nevertheless, a better understanding of the cathepsins 
biology of humans will empower new generations of scientists to find the best treatments to a broad spectrum of diseases involving cathepsins. 
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Figure Legend 
Figure 1. Figure 1. Lifecycle of cathepsin B. Inactive forms of enzymes, after post-translation 
modifications at endoplasmatic reticulum (ER) are, via Golgi complex (GC), are directed to lysosomes (L), 
cytosol or extracellular matrix. With location there function may differ, but main role stays to insure 
homeostasis and survival of the cell. Homeostasis may be corrupt due to stress cell was exposed to 
(infections, inflammations, chronic diseases, etc.) To insure their goal, they are living lysosomes within 
macrovesicles, exosomes or oncosomes. All of these cathepsin B also can be delivered by the 
messengers of intercellular communication -extracellular vesicles vesicles have purpose to provide optimal 
conditions for proteolytic activity of cathepsin B (e.g. pH) induce migration, invasion and if autophagy 
doesn`t succeed, cathepsin B activate apoptosis, trying to control damage.  
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Table 1: Main isoforms of Cathepsin B and their function 
Wild type or splice variant Tumor/health tissue Function Localization 
Main transcript (13 exons), 
 
 
 
 
Main transcript (11 exons 
lacking exons 2+3),  
 
 
 
 
 
 
 
Main transcript(12 exons) 
lacking exon 2 
-COS cells(green monkey 
adherent fibroblasts[1]),  
-human cultured articular 
chondrocytes and 
polyclonal T/C-28a2 
chondrocyte cell line[2], 
-human rheumatoid 
synovial tissue[3]; 
-human colon 
adenocarcinoma  
( tumor and mucosa[4]) 
-human breast 
adenocarcinoma[5] 
-human melanoma[5] 
 
 
Cellular 
metabolism[6] 
 
 
 
Enzyme, 
Cell death[7], 
Eukaryotic 
translation[1] 
Lysosome[8] 
 
 
 
 
Mitochondria[9] 
Cytoplasm[10] 
or nuclei[1] 
 
 
 
 
 
 
Extracellular 
space[8, 9] 
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Highlights: 
• Cathepsins represent a group of cysteine proteases  
• Cathepsins maintain homeostais in normal and pathological states of the cell 
• Cathepsin B role in anticancer therapy is diverse 
• Modulation of Cathepsin B regulates autophagy 
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